Follow below to not miss cancer knowledge~ 1 Three Major Therapies for Lung Cancer Have Shortcomings, Urgent Need for Innovative Drugs In recent years, significant progress has been made in the treatment of advanced non-small cell lung cancer, with a growing variety of therapeutic drugs leading to a triad of targeted, immunotherapy, and chemotherapy. Targeted … Read more
Introduction Protein drugs have the potential to induce immunogenicity, which can affect efficacy and even jeopardize life. New models of biotherapy, such as antibody-drug conjugates (ADC), fusion proteins, and pegylation, carry non-native human protein sequences and/or structural motifs, which may increase their immunogenicity risk. Therefore, comprehensive risk assessments, strategies, and analyses are needed to monitor … Read more
This article is compiled from Professor Song Zhengbo of Zhejiang Provincial Cancer Hospital.“Current Status and Development Challenges of ADC Drugs”. Song Zhengbo Doctor of Oncology, Associate Chief Physician, Associate Professor, Master’s Supervisor More than 100 years ago, the father of immunology, Paul Ehrlich, first proposed the concept of “magic bullet,” which refers to selectively delivering … Read more
1. Overview Antibody-drug conjugates (ADCs) rejuvenate the concept of targeted chemotherapy by coupling cytotoxic payloads to antibodies. The first stage of the complex intracellular toxin delivery process of ADCs is endocytosis. Analyzing the endocytic action of target receptors and ADCs can greatly advance preclinical research, clinical translation, and patient treatment outcomes. The in vitro efficacy … Read more
Since the first ADC drug Mylotarg® (gemtuzumab ozogamicin) was approved by the FDA in 2000, as of December 2021, a total of 14 ADC drugs have been approved globally for hematological malignancies and solid tumors, and currently, there are over 100 ADC candidates at various stages of clinical trials. Recently, the journal Signal Transduction and … Read more
Bispecific antibodies are antibodies that can bind to two different antigens simultaneously, providing greater flexibility in their mechanisms of action. Bispecific antibodies have achieved success in hematologic malignancies, with two bispecific antibodies already approved for market: blinatumomab, targeting CD19/CD3, and Mosunetuzumab, targeting CD20/CD3. Additionally, numerous bispecific antibodies targeting hematologic cancers have shown impressive efficacy in … Read more
▉ Introduction Antibody-drug conjugates (ADCs) are currently developing rapidly, utilizing antibodies to selectively deliver cytotoxic drugs to tumor sites. As of May 2021, the U.S. Food and Drug Administration (FDA) has approved 10 ADCs, including Adcetris®, Kadcyla®, Besponsa®, Mylotarg®, Polivy®, Padcev®, Enhertu®, Trodvy®, Blenrep®, and Zynlonta™ for use as monotherapy or in combination for the … Read more
ADCs are currently the trending molecules, sweeping across the globe, with 15 ADC drugs approved for market entry worldwide, and hundreds more under development. Various BD transactions continuously stimulate interest, and these phenomena precisely illustrate the future prospects of ADCs. BD Overview According to incomplete statistics, in the first quarter of 2024, there were 10 … Read more
Previous Reviews 2023 Overview of Antibody Drug Industry Development History of Monoclonal Antibodies, This Article is Enough! Brief Discussion on the Mechanism of Action and Advantages/Disadvantages of Antibodies How to Name Monoclonal Antibodies, Read This! Magic Bullet – ADC Antibody-drug conjugates (ADC) are a class of targeted biological agents composed of an antibody, a linker, … Read more
Introduction Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies that target specific antigens to small-molecule cytotoxic drugs through linkers, combining the powerful killing effects of traditional small-molecule chemotherapy with the tumor-targeting properties of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin (brand name: Mylotarg)) was approved for the treatment of CD33-positive acute myeloid leukemia, dozens … Read more